The Royal Institution for the Advancement of Learning / Mcgill University

The Hospital for Sick Children

Los Angeles Biomedical Research Institute at Harbor-ucla Medical Center

University of Alberta

Donald Christopher Sheppard

John E Edwards, Jr

Ashraf S Ibrahim

Yue Fu

Scott G Filler

Susmita Sarkar

Todd Lambert Lowary

Benjamin Alfred William Rufus Ralph

Perrin Baker

Mark Jae Lee

Noor Alnabelseya

Lynne P Howell

Brendan Snarr

Natalie Bamford

Amira Ibrahim Aly Mohamed Khalil

Dustin Little

Brad J Spellberg

Bradley J Spellberg

Lynne Howell

It is provided novel anti-galactofuranose antibodies and their use for diagnosis of and/or treating aspergillosis, and for the design of chimeric antigen receptor T-cells, wherein single chain variable fragment of the antibodies, such as a heavy chain variable region or a light chain variable region, is fused via a spacer and a transmembrane domain to a signaling endodomain to generate an expression cassette that will be integrated into a T cell.

Anti-galactofuranose antibodies for detecting and treating aspergillosis

The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.

Soluble bacterial and fungal proteins and methods and uses thereof in inhibiting and dispersing biofilm

Abloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

Pharmaceutical compositions and methods to vaccinate against candidiasis

Abloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis

Growing community of inventors

Westmount, Canada

Donald Christopher Sheppard